Merck Sharp + Dohme Corp.

Mochida Pharmaceutical Co., Ltd.

Merck + Co., Inc.

Mochida Pharmacuetical Co., Ltd.

Cameron James Smith

Yi-Heng Chen

Amjad Ali

Peter J Sinclair

Zhijian Lu

Hong Li

Christopher Francis Thompson

Tomokazu Hirabayashi

James M Balkovec

Ting Zhang

William J Greenlee

Samuel Chackalamannil

Liangqin Guo

Subharekha Raghavan

Shouwu Miao

Jiayi Xu

John E Stelmach

Julianne A Hunt

Yili Chen

Alan Whitehead

Gayle E Taylor

Joie Garfunkle

Nazia Quraishi

Hiroshi Nagasue

John Qiang Tan

Yong Zhang

Guoqing Li

Takashi Mizuno

Jianmin Fu

XiaoXia Qian

Qiaolin Deng

Ramzi Farah Sweis

Petr Vachal

Debra L Ondeyka

Rui Zhang

Dann Parker

Yoshitaka Maeda

Raphaelle Berger

Gang Ji

Florida Kallashi

Isao Sakurada

Falong Jiang

Adrian A Dowst

Hong-Dong Li

Mika Sekioka

Joann M Napolitano

Sander G Mills

Emma R Parmee

Donald W Graham

Steven L Colletti

Jianming Bao

Sherman Tim Waddell

Dooseop Kim

Tin-Yau Chan

Derun Li

Wanying Sun

Linda Brockunier

Xibin Liao

Jiang Chang

Guizhen Dong

Gool F Patel

Edward C Sherer

Sriram Tyagarajan

Liya Chen

Jian Guo

Kake Zhao

Keith Rosauer

Louis-Charles Campeau

Jonathan A Groeper

Olga Ornoski

Xiaoqing Han

Richard Beresis

Kouki Ogawa

Jennifer Kowalchick

Xiaoxia Qian

Samantha E Adamson

Gayle E Hallett

William John Greenlee

Linda L Brockunier

Olga A Ornoski

Raphelle Berger

John Stelmach

Mika Katsuno

Tin Yan Chan

Jennifer E Kowalchick

The invention provides compounds of the Formula (I) or a pharmaceutically acceptable salts thereof, wherein X, Y, Z, R, R, R, R, and the subscripts m, p, and q are as described herein. The compounds or their pharmaceutically acceptable salts can modulate the body's production of cyclic guanosine monophosphate ('cGMP'), and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention also provides pharmaceutical compositions which comprise compounds of Formula (I) or pharmaceutically acceptable salts thereof. The invention also relates to methods for use of the compounds or their pharmaceutically acceptable salts in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose.

Soluble guanylate cyclase stimulators

In its many embodiments, the present invention provides a novel class of benzamide compounds represented by Formula (I) or pharmaceutically acceptable salts or solvates thereof, or pharmaceutical compositions comprising one or more said compounds or pharmaceutically acceptable salts or solvates thereof, and methods for using said compounds or pharmaceutically acceptable salts or solvates thereof for treating or preventing a thromboses, embolisms, hypercoagulability or fibrotic changes. 

Factor IXa inhibitors

The present invention provides compounds of Formula (I) and pharmaceutical compositions comprising compounds of Formula I, and methods for using compounds of Formula I for treating or preventing thromboses, embolisms, hypercoaguability or fibrotic changes.

Compounds having the structure of Formula (I), including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and may be useful for raising HDL-cholesterol and reducing LDL-cholesterol in human patients and for treating or preventing atherosclerosis. The chemical compounds that are disclosed cholesterol ester transfer protein (CETP) and are expected to have utility in raising HDL-C, lowering LDL-C, and in the treatment and prevention of atherosclerosis. 

Spirocyclic CETP inhibitors

The present invention provides a compound of Formula (I) wherein

The present invention provides a compound of Formula (I) where A is a heterocycle ring system and B is a heterocycle ring system or aryl ring system, and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes.

A compound of Formula (I): or a pharmaceutically acceptable salt thereof, are capable of modulating the body's production of cyclic guanosine monophosphate ('cGMP') and are generally suitable for the therapy and prophylaxis of diseases which are associated with a disturbed cGMP balance. The invention furthermore relates to processes for preparing compounds of Formula I, or a pharmaceutically acceptable salt thereof, for their use in the therapy and prophylaxis of the abovementioned diseases and for preparing pharmaceuticals for this purpose, and to pharmaceutical preparations which comprise compounds of Formula (I) or a pharmaceutically acceptable salt thereof. 

Soluble guanylate cyclase activators

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. In the compound of Formula I, Ais a substituted phenyl group or indanyl group. Formula (I). 

Cyclic amine substituted oxazolidinone CETP inhibitor

Compounds having the structures of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis: In the compounds of Formula I, B or Ris a phenyl group which has an ortho aryl, heterocyclic, benzoheterocyclic or benzocycloalkyl substituent, and one other position on the 5-membered ring has an aromatic, heterocyclic, cycloalkyl, benzoheterocyclic or benzocycloalkyl substituent connected directly to the ring or attached to the ring through a &#x2014;CH&#x2014;.

CETP inhibitors

Compounds having the structure of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. The compounds have 3 cyclic groups connected by single bonds, as for example triphenyl, which are attached directly to the ring of formula I or attached at the position B. 

1,3-oxazolidin -2-one derivatives useful as CETP inhibitors

The compounds of Formula I are pro-drugs of CETP inhibitors having a central oxazolidinone ring. The compounds cyclize by the elimination of HX to form an oxazolidinone ring after administration to a patient. 

Prodrugs of oxazolidinone CETP inhibitors

Compounds of Formula I, including pharmaceutically acceptable salts of the compounds, are CETP inhibitors, and are useful for raising HDL-cholesterol, reducing LDL-cholesterol, and for treating or preventing atherosclerosis. 

1,3-oxazolidin-2-one derivatives useful as CETP inhibitors

Growing community of inventors

Lawrenceville, NJ, United States of America

Cameron James Smith